RecruitingEndometrial Cancer
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
Eligible age
18+ yrs
Accepts
Women
Locations
11 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
Sponsor: Faeth Therapeutics
You may qualify if…
- ✓ Histologically confirmed diagnosis of endometrioid endometrial carcinoma.
- ✓ Documented evidence of advanced or recurrent endometrial cancer that is not amenable to surgery/radiation for curative intent.
- ✓ Participant has received at least 1 but not more than 4 prior systemic therapies. Prior therapy must include platinum-based chemotherapy and a checkpoint inhibitor, either separately or in combination. If a subject has been unable to be treated with checkpoint inhibitor in the past due to medical contraindications, consult with Medical Monitor.
- ✓ PI3K/AKT/mTOR pathway gene alteration identified.
- ✓ At least 1 measurable target lesion according to RECIST v1.1
- ✓ Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 at Screening.
- ✓ Non-pregnant, non-lactating females who are postmenopausal, surgically sterile or who agree to use effective contraceptive methods..
You may not qualify if…
- ✕ Participants with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study
- ✕ Active malignancy (except for endometrial cancer, definitively treated in-situ carcinomas \[e.g., breast, cervix, bladder\], or basal or squamous cell carcinoma of the skin) within the past 24 months prior to treatment. Fully resected localized malignancies are eligible.
- ✕ Gastric feeding tube (gastrostomy tube), gastrointestinal malabsorption, gastrointestinal anastomosis, bowel obstruction, or any other condition that might affect the absorption of study treatment.
- ✕ Clinically significant (per Investigator judgement) hemoptysis or tumor bleeding.
- ✕ Significant cardiovascular impairment.
- ✕ Active, uncontrolled (requiring systemic antimicrobial therapy) infection.
- ✕ Concurrent participation in another therapeutic clinical trial.
- ✕ Prior radiation therapy within 21 days prior to start of study treatment.
Where it's recruiting
California
La Jolla · San Francisco
Florida
Miami Beach · St. Petersburg · West Palm Beach
Maryland
Brandywine
Minnesota
Maple Grove
New York
Albany · New York
Ohio
Cincinnati
Oregon
Eugene · Portland
Pennsylvania
Doylestown · Pittsburgh
South Dakota
Sioux Falls
Texas
El Paso · The Woodlands
Virginia
Fairfax
Source: ClinicalTrials.gov · NCT06463028 · last updated 2025-12-24